Previous 10 | Next 10 |
BILLERICA, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Summary Total revenue of $16.1 million, a decrease of 7% year-over-year on a reported a...
BILLERICA, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Officer, will participate in the virtual 2020 Oppenheimer Fall MedTech Summit taking place Thursday, N...
Conformis (CFMS) expects Q3 total revenue to decline 7% Y/Y to ~$16.1M vs. consensus of $13.04M, comprising of royalty revenue of $0.1M and product revenue of ~$16M.U.S. product revenue of to drop 7% Y/Y to ~$14.1M; Rest of world product revenue to decrease 7% Y/Y to ~$1.8M and 10% ...
BILLERICA, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) today announced preliminary, unaudited, revenue results for the third quarter ended September 30, 2020. Expected Q 3 Summary: Total revenue of approximately $16.1 million, down 7% year-...
BILLERICA, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) today announced 510(k) clearance by the U.S. Food and Drug Administration of the Company’s new Cordera™ Hip System. The first product in the Conformis hip product line, the Confo...
Conformis (CFMS) inks agreement with an institutional investor for the purchase and sale for $17.25M of (i) 8,512,088 shares of its common stock and accompanying warrants to purchase up to 8,512,088 shares of common stock and (ii) pre-funded warrants to purchase up to 9,492,953 shares of comm...
BILLERICA, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has entered into a definitive agreement with a healthcare focused institutional investor to sell to the investor, in a registered direct offering priced at-the-market under Nasdaq rules, (...
BILLERICA, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) will participate in the 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 21-23, 2020 in a virtual format. Mark Augusti, President and Chief Executive Officer, and...
BILLERICA, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) will participate in the upcoming 2020 H.C. Wainwright 22 nd Annual Global Investment Conference, to be held virtually on September 14-16, 2020. Mark Augusti, President and Chief Executive Officer, and ...
BILLERICA, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and members of the Company’s executive management team will participate in the 2020 Wells Fargo Virtual Healthcare Conference t...
News, Short Squeeze, Breakout and More Instantly...
BILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quarter ended June 30, 2022, after the mark...
BILLERICA, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced results of a published study that investigated the characteristic shapes of knees to see if typica...
BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will part...